|
US2020247769A1
|
|
Benzothiadiazepine compounds and their use as bile acid modulators
|
|
US2020247768A1
|
|
Benzothiazepine compounds and their use as bile acid modulators
|
|
WO2020161216A1
|
|
Benzothiazepine compounds and their use as bile acid modulators
|
|
WO2020161217A1
|
|
Benzothiadiazepine compounds and their use as bile acid modulators
|
|
US2020046758A1
|
|
Oral cholestyramine formulation and use thereof
|
|
US2020046757A1
|
|
Cholestyramine pellets, oral cholestyramine formulations, and uses thereof
|
|
US2020049611A1
|
|
In vitro method for determining the adsorbing capacity of an insoluble adsorbant
|
|
US2019367467A1
|
|
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
PE20210182A1
|
|
ODEXIBAT CRYSTAL MODIFICATIONS
|
|
TW202015699A
|
|
Benzothia(di)azepine compounds and their use as bile acid modulators
|
|
US2020046636A1
|
|
Oral cholestyramine formulation and use thereof
|
|
CA3071285A1
|
|
Cholestyramine granules, oral cholestyramine formulations and use thereof
|
|
US2020046635A1
|
|
Oral cholestyramine formulation and use thereof
|
|
WO2019032027A1
|
|
Cholestyramine pellets, oral cholestyramine formulations and use thereof
|
|
US2017224719A1
|
|
Cholestyramine pellets and methods for preparation thereof
|
|
US2017224720A1
|
|
Oral cholestyramine formulation and use thereof
|
|
US2017224721A1
|
|
Oral cholestyramine formulation and use thereof
|
|
WO2017138878A1
|
|
Oral cholestyramine formulation and use thereof
|
|
EP3413877A1
|
|
Oral cholestyramine formulation and use thereof
|
|
CN108601739A
|
|
Cholestyramine pill and preparation method thereof
|
